DK1066049T3 - Farmaceutiske præparater, der er beregnet til langvarig frigivelse af peptider og fremgangsmåde til fremstilling af disse - Google Patents

Farmaceutiske præparater, der er beregnet til langvarig frigivelse af peptider og fremgangsmåde til fremstilling af disse

Info

Publication number
DK1066049T3
DK1066049T3 DK99910418T DK99910418T DK1066049T3 DK 1066049 T3 DK1066049 T3 DK 1066049T3 DK 99910418 T DK99910418 T DK 99910418T DK 99910418 T DK99910418 T DK 99910418T DK 1066049 T3 DK1066049 T3 DK 1066049T3
Authority
DK
Denmark
Prior art keywords
peptides
preparation
methods
pharmaceutical compositions
sustained release
Prior art date
Application number
DK99910418T
Other languages
Danish (da)
English (en)
Inventor
Marc Pellet
Frederic Bismuth
Original Assignee
Sod Conseils Rech Applic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic
Application granted granted Critical
Publication of DK1066049T3 publication Critical patent/DK1066049T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
DK99910418T 1998-03-25 1999-03-22 Farmaceutiske præparater, der er beregnet til langvarig frigivelse af peptider og fremgangsmåde til fremstilling af disse DK1066049T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9803667A FR2776520B1 (fr) 1998-03-25 1998-03-25 Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
PCT/FR1999/000667 WO1999048517A1 (fr) 1998-03-25 1999-03-22 Compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation

Publications (1)

Publication Number Publication Date
DK1066049T3 true DK1066049T3 (da) 2003-09-29

Family

ID=9524472

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99910418T DK1066049T3 (da) 1998-03-25 1999-03-22 Farmaceutiske præparater, der er beregnet til langvarig frigivelse af peptider og fremgangsmåde til fremstilling af disse

Country Status (19)

Country Link
US (1) US6503534B1 (es)
EP (1) EP1066049B1 (es)
JP (1) JP4162381B2 (es)
AR (1) AR020062A1 (es)
AT (1) ATE241377T1 (es)
AU (1) AU756148B2 (es)
CA (1) CA2324901C (es)
CZ (1) CZ298941B6 (es)
DE (1) DE69908326T2 (es)
DK (1) DK1066049T3 (es)
ES (1) ES2200507T3 (es)
FR (1) FR2776520B1 (es)
HU (1) HU228903B1 (es)
IL (2) IL138533A0 (es)
NO (1) NO324621B1 (es)
PL (1) PL197775B1 (es)
PT (1) PT1066049E (es)
RU (1) RU2224538C2 (es)
WO (1) WO1999048517A1 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
CN100509053C (zh) * 2002-09-27 2009-07-08 赞塔里斯有限公司 持续释放的药物活性肽施用形式及其制备方法
WO2004087102A2 (en) * 2003-03-26 2004-10-14 Teva Pharmaceutical Industries Ltd. A process for preparing a pharmaceutical active ingredient with high specific surface area
EP3025722B1 (en) 2003-10-03 2020-05-27 Thorn BioScience, LLC Process for the synchronization of ovulation for timed breeding without heat detection
JP2007514752A (ja) * 2003-12-16 2007-06-07 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス Ｇｌｐ−１医薬組成物
CA2552757A1 (en) * 2004-01-13 2005-08-04 Vasogenix Pharmaceuticals, Inc. Methods of using cgrp for cardiovascular and renal indications
US7976847B2 (en) * 2004-01-13 2011-07-12 Vasogenix Pharmaceuticals, Inc. Controlled release CGRP delivery composition for cardiovascular and renal indications
WO2005070445A2 (en) * 2004-01-13 2005-08-04 Vasogenix Pharmaceuticals, Inc. Methods for treating acute myocardial infarction by calcitonin gene related peptide and compositions containing the same
US7772182B2 (en) * 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
GB0428151D0 (en) 2004-12-22 2005-01-26 Novartis Ag Organic compounds
GB0511269D0 (en) * 2005-06-02 2005-07-13 Creative Peptides Sweden Ab Sustained release preparation of pro-insulin C-peptide
EP2409753B1 (en) * 2005-07-28 2017-07-19 Carbon Sink Inc. Removal of carbon dioxide from air
GB0517627D0 (en) 2005-08-30 2005-10-05 Tyco Electronics Ltd Uk Bus-bar and connector
CA2634034A1 (en) 2005-12-20 2007-06-28 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US20070219811A1 (en) * 2006-03-16 2007-09-20 Kim John S Method for using an internet-based CRM application to create an on-line leads marketplace
CA2671925A1 (en) * 2006-12-21 2008-07-10 Stryker Corporation Sustained-release formulations comprising crystals, macromolecular gels, and particulate suspensions of biologic agents
EP2142207A4 (en) * 2007-04-04 2013-01-16 Theratechnologies Inc PHARMACEUTICAL FORMULATIONS OF GHRH MOLECULES
TWI442932B (zh) 2008-02-11 2014-07-01 Ferring Int Ct Sa 以ＧｎＲＨ拮抗劑治療攝護腺癌的方法
EP2926825A1 (en) 2008-06-27 2015-10-07 Duke University Therapeutic agents comprising elastin-like peptides
PL2421545T3 (pl) 2009-04-23 2018-05-30 Jbs United Animal Health Ii Llc Sposób i kompozycja do synchronizacji czasu inseminacji
EP2424503B1 (en) 2009-05-01 2017-07-05 Ferring BV Composition for the treatment of prostate cancer
TW201043221A (en) * 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) * 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
JP5801807B2 (ja) * 2009-08-14 2015-10-28 フェーズバイオ ファーマシューティカルズ，インコーポレイテッド 修飾された血管作動性腸管ペプチド
WO2011085957A2 (en) * 2010-01-13 2011-07-21 Ipsen Pharma S.A.S. Process for the preparation of pharmaceutical compositions for the sustained release of somatostatin analogs
PL2632934T3 (pl) 2010-10-27 2017-06-30 Ferring B.V. Sposób wytwarzania degareliksu i jego związków pośrednich
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
US9561262B2 (en) 2011-06-06 2017-02-07 Phasebio Pharmaceuticals, Inc. Use of modified vasoactive intestinal peptides in the treatment of hypertension
DE102011114864A1 (de) 2011-10-05 2013-04-11 Acino Ag Verfahren zur Herstellung einer homogenen Pulvermischung und Verfahren zur Herstellung eines Implantats sowie Implantat
AR092840A1 (es) 2012-06-01 2015-05-06 Ferring Bv Elaboracion de degarelix
WO2014085674A1 (en) 2012-11-28 2014-06-05 Jbs United Animal Health Ii Llc Method for synchronizing time of insemination in gilts
EP2823808A1 (en) 2013-07-09 2015-01-14 Ipsen Pharma S.A.S. Pharmaceutical composition for a sustained release of lanreotide
TW201605488A (zh) 2013-10-15 2016-02-16 大塚製藥股份有限公司 用以預防及／或治療多囊腎病之藥物
EP2910255A1 (en) * 2014-02-19 2015-08-26 MedSkin Solutions Dr. Suwelack AG Methods for the production of biopolymers with defined average molecular weight
TW201625218A (zh) * 2014-04-18 2016-07-16 Ｊｂｓ聯合動物保健有限責任公司 製造含ｇｎｒｈ凝膠之方法
EP3139949B1 (en) 2014-05-08 2020-07-29 Phasebio Pharmaceuticals, Inc. Compositions comprising a vip-elp fusion protein for use in treating cystic fibrosis
JP6824888B2 (ja) 2015-02-09 2021-02-03 フェーズバイオ ファーマシューティカルズ，インコーポレイテッド 筋肉の疾患および障害を治療するための方法および組成物
WO2020170185A1 (en) * 2019-02-21 2020-08-27 Dr. Reddy’S Laboratories Limited Substantially pure lanreotide or its salt & process thereof
GR1009814B (el) * 2019-07-29 2020-09-11 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει ενα πεπτιδιο αναλογο σωματοστατινης
CN110577567A (zh) * 2019-09-03 2019-12-17 杭州诺泰澳赛诺医药技术开发有限公司 一种制备高比表面积活性多肽或蛋白的方法
CN118302211A (zh) * 2021-11-22 2024-07-05 Specgx有限责任公司 可注射缓释药物组合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69005800T2 (de) * 1989-05-01 1994-05-19 Alkermes Inc Verfahren zur herstellung von kleinen partikeln von biologisch aktiven molekülen.
US5595760A (en) * 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions

Also Published As

Publication number Publication date
HUP0101545A3 (en) 2001-12-28
FR2776520B1 (fr) 2000-05-05
CZ298941B6 (cs) 2008-03-19
IL138533A0 (en) 2001-10-31
AU756148B2 (en) 2003-01-02
CZ20003432A3 (cs) 2001-02-14
PL343005A1 (en) 2001-07-30
CA2324901C (fr) 2012-01-24
DE69908326D1 (de) 2003-07-03
US6503534B1 (en) 2003-01-07
NO324621B1 (no) 2007-11-26
HUP0101545A1 (hu) 2001-11-28
NO20004741L (no) 2000-11-22
ES2200507T3 (es) 2004-03-01
EP1066049B1 (fr) 2003-05-28
WO1999048517A1 (fr) 1999-09-30
IL138533A (en) 2006-12-31
PL197775B1 (pl) 2008-04-30
EP1066049A1 (fr) 2001-01-10
JP4162381B2 (ja) 2008-10-08
HU228903B1 (en) 2013-06-28
DE69908326T2 (de) 2004-03-25
RU2224538C2 (ru) 2004-02-27
PT1066049E (pt) 2003-10-31
AU2938499A (en) 1999-10-18
NO20004741D0 (no) 2000-09-22
FR2776520A1 (fr) 1999-10-01
CA2324901A1 (fr) 1999-09-30
JP2002507578A (ja) 2002-03-12
ATE241377T1 (de) 2003-06-15
AR020062A1 (es) 2002-04-10

Similar Documents

Publication Publication Date Title
DK1066049T3 (da) Farmaceutiske præparater, der er beregnet til langvarig frigivelse af peptider og fremgangsmåde til fremstilling af disse
DK0980240T3 (da) Sammensætninger med lang frigivelse og fremgangsmåde til fremstilling heraf
DK1275387T3 (da) Fremgangsmåde til fremstilling af farmaceutiske præparater af fenofibrat med höj biologisk tilgængelighed
NO20001409D0 (no) Karboksamidotiazolderivater, fremgangsmåte for fremstilling derav og farmasøytiske blandinger
DK1326585T4 (da) Fremgangsmåde til fremstilling af pulverformuleringer
NO992339D0 (no) Farmas°ytiske formuleringer
DK1042355T3 (da) 11beta-halogen-7alfa-substituerede estratriener, fremgangsmåde til fremstilling af farmaceutiske præparater, der indeholder disse 11beta-halogen-7alfa-substituerede estratriener, samt deres anvendelse til fremstilling af lægemidler
NO20011613L (no) Sammensetninger og fremgangsmåte for WT1-spesifikk immunterapi
DK1152765T3 (da) Ethanolat af azithromycin, fremgangsmåde til fremstilling og farmaceutiske sammensætninger deraf
DK1372686T3 (da) Fremgangsmåder og sammensætninger til peptidsyntese
NO20016277D0 (no) Systemer og fremgangsmåter for aerolisering av farmasöytiske formuleringer
EE200100134A (et) Kiiresti vabastav tablett
DK1202965T3 (da) Indolderivater, fremgangsmåde til fremstilling deraf, farmaceutiske præparater indeholdende disse og deres medicinske anvendelse
DK1181397T3 (da) Rhodium-elektrokatalysator og fremgangsmåde til fremstilling af denne
DK0991654T3 (da) Hidtil ukendte derivater af 2-(iminomethyl)aminophenyl, deres fremstilling, deres anvendelse til medikamenter og farmaceutiske præparater indeholdende samme
DK0973763T3 (da) Hidtil ukendte 2-(iminomethyl)aminophenylderivater, fremstilling af disse, anvendelse af disse i egenskab af lægemidler og farmaceutiske præparater indeholdende disse
DK1265482T3 (da) Vandige formulationer og fremgangsmåde til fremstilling af samme
DK0977812T3 (da) Asfaltsammensætninger og fremgangsmåder til fremstilling deraf
DK0991415T3 (da) Faste, oralt indgivelige dosisformer for ribavirin og fremgangsmåde til fremstilling af disse
IS2841B (is) Samstæða hluta og lyfjasamsetningar
DK1049721T3 (da) Syntetiske polysaccharider, fremgangsmåde til fremstilling heraf og farmaceutiske præparater indeholdende disse
DK1015433T3 (da) Substituerede 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-oler, fremgangsmåder til fremstilling af disse og deres anvendelse som lægemidler
NO20022022D0 (no) N-guanidinoalkylamider, deres fremstilling, deres anvendelse og farmasöytiske preparater omfattende disse
DK1171444T3 (da) Pyridothienodiazepiner, fremgangsmåde til fremstilling af disse og farmaceutiske præparater indeholdende disse
IS6402A (is) Nýjar greinóttar setnar amínó afleiður af 3-amínó-1-fenýl-1H[1,2,4]tríazóli, aðferðir til framleiðslu á þeim og lyfjasamsetningar sem innihalda þær